Exelixis Inc. (NASDAQ:EXEL) today announced the positive results from
coBRIM, the phase 3 pivotal trial conducted by Exelixis’ collaborator
Genentech, a member of the Roche Group, evaluating cobimetinib, a
specific MEK inhibitor discovered by Exelixis, in combination with
vemurafenib in previously untreated patients with unresectable locally
advanced or metastatic melanoma harboring a BRAF V600 mutation.
Sign-up for Exelixis Announces Positive Results from Phase 3 Pivotal Trial of Cobimetinib in Combination with Vemurafenib in Patients with BRAF V600 Mutation-Positive Advanced Melanoma investment picks
Strongly Positive Results, Presented at European Society for Medical Oncology (ESMO) 2014 Congress, Demonstrated Oncotype DX® Prostate Cancer Test was an Independent Predictor of Tumor Aggressiveness
Study, Including 20% African-American Men, Confirmed Similar Predictive Outcomes Regardless of Race REDWOOD CITY, Calif.
Sign-up for Genomic Health Announces Positive Results from Latest Clinical Validation Study of Oncotype DX® as Predictor of Near- and Long-term Outcomes in Racially Diverse Group of Prostate Cancer Patients investment picks
Achieved Primary 30 Day Endpoint Patients in CARENET Trial had significantly lower incidence of new ischemic lesions compared to historical control groups of non-mesh covered carotid stents
BOSTON , Sept.
Ipsen (Euronext: IPN; ADR: IPSEY) today announced positive results from
the phase III study of triptorelin pamoate 11.25 mg (Decapeptyl ®
3 months) administered subcutaneously in patients with locally advanced
or metastatic prostate cancer at the European Association of Urology
(EAU) 14 th Central European Meeting in Cracow, Poland (10-12
The primary objective of the study was to assess the efficacy and safety
profile of the sustained-release triptorelin pamoate 11.25 mg (Decapeptyl ®
3 months) formulation when administered by the subcutaneous route in men
with locally advanced or metastatic prostate cancer.
Sign-up for Genomic Health Announces Presentation of Positive Results from Latest Prostate Cancer Clinical Validation Study at the European Society for Medical Oncology (ESMO) 2014 Congress investment picks
- Alirocumab, an investigational treatment for hypercholesterolemia, showed a 62 percent reduction in LDL-C compared to placebo at 24 weeks on top of maximally-tolerated lipid-lowering therapy in ODYSSEY LONG TERM trial -
PARIS and TARRYTOWN, N.Y. , Aug.
Alirocumab, an investigational treatment for hypercholesterolemia, showed a 62 percent reduction in LDL-C compared to placebo at 24 weeks on top of maximally-tolerated lipid-lowering therapy in the ODYSSEY LONG TERM trial
TARRYTOWN, New York and PARIS , Aug.
Teva Pharmaceutical Industries Ltd., (NYSE:TEVA) today announced the
initiation of a rolling New Drug Application (NDA) submission to the
U.S. Food and Drug Administration for hydrocodone bitartrate
extended-release tablets designed with Teva’s proprietary technology
providing potential abuse-deterrent properties (CEP-33237) as allowed
for fast track designated products.
Sign-up for Teva Announces Initiation of New Drug Application and Positive Results from Second Human Abuse Liability Study for CEP-33237 (Hydrocodone Bitartrate) Extended-Release Tablets investment picks
SOUTH SAN FRANCISCO, CA --
Trial meets primary endpoint with I.V. CR845 showing highly statistically significant reductions (p <0.0001) in scores for "drug liking," as well as "feeling high", "overall liking", and "take drug again" when compared to I.V. pentazocine, a Schedule IV opioid analgesic Results suggest potential for I.V. CR845 to be first Schedule V or non-scheduled peripheral opioid for acute pain Conference Call/Webcast at 9:00 a.m. ET today
SHELTON, Conn., Oct.
Sign-up for Ampio Announces Very Positive Results of the Open Label Portion of the Multiple Intra-articular Injections Study of Ampion™ in Patients with Osteoarthritis of the Knee at Week Six of the Trial investment picks
Sign-up for Kite Pharma Announces Patients With Aggressive Non-Hodgkin's Lymphoma Experience Positive Results After Receiving Anti-CD19 Chimeric Antigen Receptor (CAR) T Cells at the National Cancer Institute (NCI) investment picks
IRVINE, CA--(Marketwired - August 19, 2014) - Vivakor Inc. (PINKSHEETS: VIVK) announced GAAP based financial results for the quarter ended June 30, 2014.
Independent. Insightful. Trusted. Morningstar provides stock market analysis; equity, mutual fund, and ETF research, ratings, and picks; portfolio tools; and option, hedge fund, IRA, 401k, and 529 plan research. Our reliable data and analysis can help both experienced enthusiasts and newcomers.